Articles
View all articles-
After swallowing bitter pill, Ranbaxy set to revive sales in US
Despite the reputational damage and financial hit Ranbaxy has taken, resolving the lawsuit puts the company on firmer ground to start reviving sales to its biggest market, say analysts. #Business #Ranbaxy Laboratories #WhatNext #Ranbaxy Laboratories Ltd #US Justice Department #Ranbaxy $500 million fraud
-
Markets end flat despite low WPI, Ranbaxy recoups losses
The BSE Sensex closed at 19726.27 , up 0.18 percent and Nifty ended at 5997.10, up 0.28 percent. #Tata Steel #Investing #Ranbaxy Laboratories #State Bank of India #Dr. Reddy's Laboratories #WPI inflation #MarketClose
-
Ranbaxy pleads guilty to felony, to pay $500 mn in settlement
The FDA had accused the company of falsifying data and test results in drug applications and halted reviews of drugs made at a plant in northern India. #Ranbaxy Laboratories #NewsTracker #Drug safety
Blog posts
View all blog posts-
India, US firms join hands to make HIV war affordable
A big US pharma company has finally taken proactive measures (learning from history no doubt) to license innovative drugs to low-cost drug makers in India so that they reach the people who need them the most. #Ranbaxy Laboratories #GeekSpeak #HIV/AIDS #Antiretroviral drug #Gilead Sciences
Wire
-
Keralanext
It was perhaps too late for Daiichi to exit Ranbaxy after USFDA action
Three months after Daiichi Sankyo, Japan's number three drugmaker, entered a deal in June 2008 to buy 63.9% stake in Ranbaxy from the controlling shareholder group led by brothers Malvinder Singh and Shivinder Singh for $4.2 billion, the USFDA issued imp #Daiichi Sankyo #U.S. Department of Justice #India
-
Calcutta Telegraph
Ranbaxy past troubles Daiichi
Mumbai, May 22: Daiichi Sankyo Company of Japan is weighing its legal options against the former promoters of Ranbaxy Laboratories for misleading it about the investigations by the US Food & Drugs Administration (FDA) and the US Department of Justice (Do #Daiichi Sankyo #Mumbai #Food and Drug Administration
-
Channel News Asia
Former Ranbaxy owners deny hiding drug probe detail
NEW DELHI: The billionaire ex-owners of Ranbaxy denied Thursday charges by the Japanese buyers of the Indian generics giant that they hid key details about a US probe into the safety of the company's drugs. Daiichi Sankyo alleged Wednesday former shareho #New Delhi #Daiichi Sankyo #India




